Доцетаксел и бисфосфонаты при гормоночувствительном раке предстательной железы

Автор: Павлов А.Ю., Гафанов Р.А., Фастовец С.В., Кравцов И.Б.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 1 т.16, 2016 года.

Бесплатный доступ

Рак предстательной железы (РПЖ) является одной из наиболее часто встречаемых форм злокачественных новообразований у мужчин. У некоторых больных могут выявляться распространенные или метастатические формы заболевания на момент постановки диагноза или после проведения начальной терапии, что может потребовать использования системного лечения, включая химиотерапию. Целью данного обзора является обобщение текущих стандартов медицинской помощи при гормоночувствительных и кастрационно-резистентных формах рака предстательной железы (КРРПЖ), в свете появившихся новых лекарственных методов лечения. Абиратерон ацетат и энзалутамид были впервые оценены у пациентов в качестве препаратов второй линии после прогрессирования опухоли при использовании доцетакселя. Показания к химиотерапевтическому применению этих препаратов могут быть расширены с включением пациентов с гормон-наивным местно-распространенным РПЖ. Тем не менее, существует некоторая неопределенность в отношении оптимальной лекарственной стратегии. Долгосрочные результаты исследований абиратерон ацетата и энзалутамида будут способствовать дальнейшему определению роли химиотерапии при раке предстательной железы, а также помогут уточнить генеральную стратегию лечения пациентов с мРПЖ.

Еще

Рак предстательной железы, химиотерапия, уровень пса, гормональная терапия, метастазы, кастрационная резистентность

Короткий адрес: https://sciup.org/14955508

IDR: 14955508

Список литературы Доцетаксел и бисфосфонаты при гормоночувствительном раке предстательной железы

Ansari J., Hussain S.A., Alhasso A., et al. Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer-current strategies and future directions. Anticancer Agents Med Chem. 2011. V. 11. No. 3. P. 296-306.
Antonarakis E.S., Kibel A.S., Adams G., et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results. J Clin Oncol. 2013. V.
Araujo J.C., Trudel G.C., Saad F., et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, doubleblind phase 3 trial. Lancet Oncol. 2013. V. 14. No. 13. P. 1307-1316.
Attard G., Sydes M.R., Mason M.D., et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol. 2014. V. 66. No. 5. P. 799-802.
Bahl A., Oudard S., Tombal B., et al. Impact of cabazitaxel on 2-year survival and palliation of tumourrelated pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013. V. 24. No. 9. P. 2402-2408.
Basch E., Loblaw D.A., Oliver T.K., et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014. V. 32. No. 30. P. 3436-3448.
Basch E.M., Somerfield M.R., Beer T.M., et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007. V. 25. No. 33. P. 5313-5318.
Beer T.M., Armstrong A.J., Rathkopf D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014. V. 371. No. 5. P. 424-433.
Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008. V. 26. No. 2. P. 242-245.
Buonerba C., Federico P., D'Aniello C., et al. Phase II trial of cisplatin plus prednisone in docetaxelrefractory castration-resistant prostate cancer patients. Cancer Chemother Pharmacol. 2011. V. 67. No. 6. P. 1455-1461.
Chi K.N., Hotte S.J., Yu EY., et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010. V. 28. No. 27. P. 4247-4254.
Cookson M.S., Lowrance W.T., Murad M.H., et al. Castration-resistant prostate cancer: AUA guideline amendment. J Urol. 2015. V. 193. No. 2. P. 491-499.
Cookson M.S., Roth B.J., Dahm P., et al. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013. V. 190. No. 2. P. 429-438.
de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011. V. 364. No. 21. P. 1995-2005.
de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010. V. 376. No. 9747. P. 1147-1154.
Dorff T.B., Tsao-Wei D.D., Groshen S., et al. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013. V. 11. No. 4. P. 416-422.
Droz J.P., Aapro M., Balducci L., et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014. V. 15. No. 9: e404-414.
Droz J.P., Muracciole X., Mottet N., et al. Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol. 2003. V. 14. No. 8. P. 1291-1298.
Fizazi K., Scher H.I., Miller K., et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castrationresistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014 а. V. 15. No. 10. P. 1147-1156.
Fizazi K., Scher H.I., Molina A., et al. Abiraterone acetate for treatment of metastatic castrationresistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol. 2012. V. 13. No. 10. P. 983-992.
Fizazi K. Laplanche A., Lesaunier F., et al. Docetaxel-estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial. J Clin Oncol. 2014 b. V. 32:5s (suppl; abstr 5005).
Gasent Blesa J.M., Giner Marco V., Giner-Bosch V., et al. Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients. Am J Clin Oncol. 2011. V. 34. No. 2. P. 155-159.
Gravis G., Boher J. M., Florence J., et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol. 2015. V. 33. Supp. l 7. Abstr. 140.
Gravis G., Fizazi K., Joly F., et al. Androgen-deprivation therapy alone or with docetaxel in noncastrate metastatic prostate cancer (GETUG-AFU 15): a randomised, openlabel, phase 3 trial. Lancet Oncol. 2013. V. 14. No. 2. P. 149-158.
Heidenreich A., Bastian P.J., Bellmunt J., et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castrationresistant prostate cancer. Eur Urol. 2014 а. V. 65. No. 2. P. 467-479.
Heidenreich A., Bracarda S., Mason M., et al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer. 2014 b. V. 50. No. 6. P. 1090-1099.
International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013. http://globocan.iarc.fr. 10 April 2015.
Italiano A., Ortholan C., Oudard S., et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castrationresistant prostate cancer. Eur Urol. 2009. V. 55. No. 6. P. 1368-1375.
James N.D., Spears M.R., Clarke N.W., et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015. V. 67. No. 6. P. 10281038.
Kantoff P.W., Schuetz T.J., Blumenstein B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSAtargeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 a. V. 28. No. 7. P. 1099-1105.
Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999. V. 17. No. 8. P. 2506-2513.
Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med. 2010 b. V. 363. No. 5. P. 411-422.
Kellokumpu-Lehtinen P.L., Harmenberg U., Joensuu T., et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013. V. 14. No. 2. P. 117-124.
Kelly W.K., Halabi S., Carducci M., et al. Randomized, doubleblind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012. V. 30. No. 13. P. 1534-1540.
Kentepozidis N., Soultati A., Giassas S., et al. Paclitaxel in combination with carboplatin as salvage treatment in patients with castrationresistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Cancer Chemother Pharmacol. 2012. V. 70. No. 1. P. 161-168.
Logothetis C.J., Basch E., Molina A., et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012. V. 13. No. 12. P. 12101217.
Mottet N., Bellmunt J., Briers E., et al. EAU Guidelines on Prostate Cancer. 2015. http://uroweb.org/guideline/prostate-cancer/. 19 April 2015.
National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: prostate cancer. http://seer.cancer.gov/. 10 April 2015.
National Institute for Health and Care Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. 2006. https://www.nice.org.uk/guidance/ta101. 10 April 2015.
OncoGenex Technologies. Comparison of cabazitaxel/prednisone alone or in combination with custirsen for 2nd line chemotherapy in prostate cancer (AFFINITY). Clinical trial: NCT01578655. 2015. https://clinicaltrials.gov/ct2/show/NCT01578655. 28 April 2015.
Parker C., Heinrich D., O'Sullivan J.M., et al. Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA). Eur J Cancer. 2011. V. 47. Suppl. 2: 3.
Parker C., Nilsson S., Heinrich D., et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 2012. V. 30. Suppl. Abstr. LBA4512.
Parker C., Nilsson S., Heinrich D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013. V. 369. No. 3. P. 213-223.
Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004. V. 351. No. 15. P. 1513-1520.
Rathkopf D.E., Smith M.R., de Bono J.S., et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014. V. 66. No. 5. P. 815-825.
Rosenthal S.A., Bae K., Pienta K.J, et al. Phase III multiinstitutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys. 2009. V. 73. No. 3. P. 672-678.
Ross R.W., Beer T.M., Jacobus S., et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate Cancer who are refractory to docetaxel. Cancer. 2008. V. 112. No. 3. P. 521-526.
Ryan C.J., Smith M.R., de Bono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013. V. 368. No. 2. P. 138-148.
Ryan C.J., Smith M.R., Fizazi K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol. 2015. V. 16. No. 2. P. 152-160.
Cabazitaxel at 20 mg/m2 compared to 25 mg/m2 with prednisone for the treatment of metastatic castration resistant prostate cancer (PROSELICA). Clinical trial: NCT01308580. 2015. http://www.clinicaltrials.gov/ct2/show/NCT01 308580?term=NCT01308580&rank=1. 6 December 2014.
Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). Clinical trial: NCT01308567. 2015. http://www. clinicaltrials.gov/ct2/show/NCT013 08567?term=NCT01308567&rank=1. 3 December 2014.
JEVTANA (cabazitaxel) package insert. http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf. 10 April 2015.
Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med. 2012. V. 367. No. 13. P. 1187-1197.
Sweeney С., Chen Y.-H., Carducci M.A., et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol. 2014. V. 32:5s (suppl; abstr LBA2).
Tannock I.F., Fizazi K., Ivanov S., et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, doubleblind randomised trial. Lancet Oncol. 2013. V. 14. No. 8. P. 760-768.
Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004. V. 351. No. 15. P. 1502-1512.
Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996. V. 14. No. 6. P. 1756-1764.
Teva Pharmaceutical Industries. Comparison of docetaxel/prednisone to docetaxel/prednisone in combination with OGX-011 in men with prostate cancer (SYNERGY). Clinical trial: NCT01188187. 2015. https://clinicaltrials.gov/ct2/show/NCT01188187. 28 April 2015.
Topalian S.L., Hodi F.S., Brahmer JR., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012. V. 366. No. 26. P. 2443-2454.

Еще

Статья научная